ScreenerHero

ACRS Aclaris Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · aclaristx.com
3.400USD-8.11%Mkt Cap: 500.48M $P/E: —

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company produ…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap500.48M USD
Enterprise Value454.93M USD
Revenue (TTM)8.22M USD
Gross Profit542.00K USD
Net Income (TTM)-64.92M USD
Revenue/Share0.06 USD
Last Price3.400 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees69
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.70
PEG—
EV/EBITDA-5.32
EV/Revenue55.35
P/S66.27
P/B4.15
EPS (TTM)-0.50
EPS (Forward)-0.79
52W Range
1.74035% of range6.530
52W High6.530 USD
52W Low1.740 USD
Profitability
Gross Margin6.93%
Oper. Margin-1469.49%
EBITDA Margin0.00%
Profit Margin-829.58%
ROE-62.98%
ROA-40.46%
Growth
Revenue Growth-8.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-47.11M USD
CapEx (TTM)111.00K USD
FCF Margin-510.65%
FCF Yield-8.39%
Net Debt-89.71M USD
Net Debt/EBITDA1.05
Balance Sheet
Debt/Equity1.49
Current Ratio3.46
Quick Ratio3.46
Book Value/Sh0.89 USD
Cash/Share0.62 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.18 USD
Upside (mean)+199.5%
Target Range4.000 USD – 16.00 USD
4.000+199.5% to mean16.00
# Analysts11
Ownership
Shares Out.147.20M
Float101.17M
Insiders2.18%
Institutions84.00%
Short Interest
Short Ratio7.5d
Short % Float12.40%
Short % Out.10.92%
Shares Short16.08M
Short (prev mo.)14.71M
Technical
SMA 505.689 (-40.2%)
SMA 2004.455 (-23.7%)
Beta0.88
S&P 52W Chg16.45%
Avg Vol (30d)3.07M
Avg Vol (10d)3.39M
Technical Indicators
RSI (14)22.3
MACD-0.4743
MACD Signal-0.2650
MACD Hist.-0.2094
BB Upper6.521 USD
BB Middle5.117 USD
BB Lower3.712 USD
BB Width54.90%
ATR (14)0.4014 USD
Vol Ratio (20d)2.61x